Tag: research

We are pleased to announce that we have awarded £4.5 million to three new, exciting research initiatives.

We praise the launch of OurBrainBank’s new policy report and share how it ties in with our research strategy and innovations around treatment for glioblastomas.

We’re driving forward cutting-edge research together, as the Foundation fulfils a ground-breaking new £1.5 million research grant 18 months early.

Researchers at the University of Toronto have identified a biomarker that can predict how aggressive meningiomas may be in those diagnosed with this type of brain tumour.

Experts at The Everest Centre are delivering a cutting-edge program of scientific research to develop pioneering new treatments for children diagnosed with low-grade brain tumours, following major new funding from The Brain Tumour Charity.

Offering coaching to promote healthy lifestyles could help reduce severe fatigue for patients following brain tumour treatment, a clinical trial has found.

The government have signed an agreement with German pharmaceutical company BioNTech to ensure their innovative vaccine research comes to England.

Researchers have found the origin of group 3 and 4 childhood medulloblastoma, which could help develop new treatments for children diagnosed with one of the most common forms of cancerous brain tumour.

New research suggests that ulixertinib may offer one of the first targeted therapies for the most common form of brain tumour in children.

A major phase III clinical trial has found that novel treatment DCVax®-L can prolong the lives of people diagnosed with a new or recurrent glioblastoma.

We are delighted to announce the appointment of the first-ever The Brain Tumour Charity Chair of Translational Neuro-Oncology at The University of Manchester’s Cancer Research Centre (MCRC).

James was first diagnosed with a brain tumour after having a seizure in 2018. Since then, he has had two awake craniotomies and a string of treatment types. Here, he shares his story on how he has navigated the uncertainty which came with it all.

The second part of our interview with Sigourney Bell, a third-year PHD candidate at the CRUK Cambridge Institute and co-Founder of Black in Cancer.

We spoke with Sigourney Bell, a third-year PHD candidate at the CRUK Cambridge Institute and co-Founder of Black in Cancer, about her experiences as a researcher.

Verbal fluency test to name animals found to identify those with persistent headaches who are more likely to have a brain tumour, and could help GPs decide who needs rapid imaging.

In this blog, Stephen tells us why it is so important to take part in clinical research. He talks us through his experience of volunteering in the Sativex clinical trial (Phase 1) and joining the Involvement Network.

We respond to preliminary overall survival data from phase III clinical trial that suggests DCVax-L may help extend survival for patients with newly-diagnosed or recurrent glioblastomas.

New Year, new research grant opportunities as The Charity is returning to traditional research funding after the pandemic pause with our substantial Future Leaders grants.

A major UK trial of cannabis-based drug Sativex in treating the most aggressive form of brain tumour is to launch at 15 NHS hospitals, following promising results from a phase I study in 27 patients.

Geneticists from Trinity College Dublin have discovered how a specific genetic mutation called H3K27M causes a devastating, incurable childhood cancer, known as diffuse midline glioma (DMG), and, in lab studies working with model cell types, successfully reverse its effects to slow cancer cell growth with a targeted drug.

If we can find a way to interrupt a cancer cell’s ability to keep dividing, we may have a key to stopping tumours growing. Researchers, Dr Wong and Dr Voon ,tells us about the discovery they made into a tumour’s ability to continuously divide.

Research we funded has added value to a clinical trial that started in 2004. Updated scientific techniques showed that some children with a medulloblastoma can safely be spared harmful treatments.

Artificial intelligence (AI) may be the key to fast and consistent renal cell tumour diagnoses, all because of work we fund on brain tumours.

Back in 2015 we launched our five year strategy ‘Defeating Brain Tumours’ and our research strategy ‘A Cure Can’t Wait’. Our manifestos were unashamedly ambitious, but we knew they had to be.